A method for separating target molecules or particles from a fibrinogen containing sample comprises: (a) trapping the said target molecules or particles in a fibrin network by converting at least partially the fibrinogen contained in the sample into fibrin; (b) retracting the said fibrin network to form a fibrin clot; (c) separating the said fibrin clot from the surrounding sample medium.

The present disclosure relates to a method for measuring fibrinogen concentration in a blood sample, which enables measuring of the concentration of the fibrinogen protein present in a blood sample from the human body. The method for measuring fibrinogen concentration of the present disclosure is convenient because an enzyme is not used. In addition, an error due to a factor affecting factor affecting in-vivo enzyme activity does not occur and measuring time is decreased since measurement for reference plasma is unnecessary. Therefore, the method achieves superior accuracy, precision and reproducibility as compared to the existing technologies and can be usefully employed for measuring fibrinogen concentration in a blood sample.

The present invention is related to a novel and direct method for measuring the fibrinogen level in a sample, which is particularly useful in emergency situations. The novel method is independent of thrombin formation and is not interfered by the presence of oral anti-coagulation drugs or other chemicals contrary to the commonly used clotting assays.

To provide a system capable of evaluating a deficiency and/or a lowered function of extrinsic coagulation factors or intrinsic coagulation factors with high sensitivity by adding new procedures and apparatuses to a blood coagulation system analysis procedure, an apparatus, or the like. A blood coagulation system analysis system includes a blood coagulation system measurement apparatus that performs blood coagulation system measurement of a blood sample; and a blood coagulation system analysis apparatus including a coagulation parameter extraction unit that extracts a coagulation parameter from a measurement result by the blood coagulation system measurement apparatus, and a blood coagulation evaluation unit that evaluates a level of blood coagulation of the blood sample on the basis of the coagulation parameter, the measurement by the blood coagulation system measurement apparatus being performed under an extrinsic system acceleration condition and an intrinsic system acceleration condition.

The present invention provides use of quinaldine red (QR) and/or a derivative thereof in preparation of a kit for detecting amyloid fibrils. The derivative includes 4-(4-dimethylaminostyryl)quinoline, and the present invention belongs to the technical field of amyloid fibril detection. Compared with traditional amyloid fibril detection probes, the QR and its derivative 4-(4-dimethylaminostyryl)quinoline have higher binding constants for binding with the amyloid fibrils; and good photobleaching performances; and in the present invention, after combined with the amyloid fibrils, both the QR and its derivative 4-(4-dimethylaminostyryl)quinoline have a fluorescence emission wavelength range that is close to a far-infrared band, and thus are more suitable for imaging a pathological tissue of a biological tissue.

Identifying in the presence of an SARS-CoV-2, infection of COVID-19 in a human subject and/or for classifying the risk of such infection progressing to a severe or critical disease, using a system functionally associated with at least one analyzer for analyzing the blood sample, is disclosed. The system includes at least one of an input interface or a transceiver, and one or more processors functionally associated therewith. A storage medium associated with the processor(s) has stored instructions to receive biographical information relating to the human subject, and instructions to receive measurements of a plurality of serum biomarkers. Further stored are instructions to apply a neural network algorithm to the measurements of the plurality of biomarkers and the biographical information, and instructions to identify, based on an output of the neural network algorithm, a COVID-19 infection or to classify the risk of such infection progressing to a severe or critical disease.

Provided are assay devices, methods and microfluidic cartridges for analysis of fluids, such as whole blood. A fibrinogen assay cartridge is adapted to measure whole blood flow rates on exposure to thrombin and measures hematocrit for a plasma fibrinogen calculation. Multiple channel cartridges are provided to allow determination of multiple assays (e.g., coagulation panel) from a single sample on a single cartridge.

An apparatus to detect blood clots based on the analysis of the blood's chromatic properties is described. The chromatic property can be determined non-evasively when used in conjunction with ECMO systems. The red, green, and blue chromatic values of a clotting site and a reference site are compared to determine if a clotting event occurred. It was discovered that, at a minimum, only the red chromatic value needs to be tested and measured to determine if a clotting event had occurred. This system can be adopted to monitor clot formation in heart surgery, heart or lung transplants or patients coupled to ECMO requiring an ability to measure the clots to a blood depth of 20 mm. Once clots are detected, the system can introduce anti-coagulants into the blood stream to reduce the clot formation.

Disclosed herein are CMP-associated proteins, collected between 10-12 weeks of gestation, that can be used to stratify the risk of later preeclampsia requiring delivery at <=35 weeks of gestation. For those that screen positive, clustering can be used to further characterize the putative subtype of the preeclampsia. Risk stratification and disease phenotype characterizations such as this can optimize prophylactic and therapeutic interventions.

Method for detecting a urinary tract infection (UTI) in a subject comprising determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject. The determined levels may then be compared with a threshold level, wherein increased levels of at least one of the biomarkers in the urine sample relative to the threshold level is indicative of the presence of a urinary tract infection. Methods for monitoring a UTI and monitoring treatment of a UTI are also provided as are companion systems or test kits.